We can't find the internet
Attempting to reconnect
Something went wrong
Hang in there while we get back on track
£520.00
It has never been this cheap. We have no record of a lower price.
£520 today · cheaper than every other day in the last 3 months
The 2023-2028 Outlook for Proliferative Diabetic Retinopathy Treatments in the United States
We'll watch every seller, every day. One email when your price arrives.
Price History & Forecast
Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.
Last 32 days · 32 data points (no recent data)
Historical
Generating forecast…
NEW HERE?
Amazon shows you one price. We show you all of them.
Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.
WHAT'S ON THIS PAGE
↑ Price chart
when this has been cheap or pricey
when this has been cheap or pricey
↑ Forecast
where the price is heading next
where the price is heading next
↓ Statistics
all-time high & low, recent range
all-time high & low, recent range
↑ Price alert
name your number, we'll email you
name your number, we'll email you
Price Distribution
Price distribution over 32 days • 1 price levels
Price Analysis
Most common price: £520 (32 days, 100.0%)
Price range: £520 - £520
Price levels: 1 different prices over 32 days
Description
This study covers the latent demand outlook for proliferative diabetic retinopathy treatments across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for proliferative diabetic retinopathy treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of proliferative diabetic retinopathy treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Alimera Sciences, Allergan, Ampio Pharmaceuticals, BCN Peptides, Genentech, Glycadia, Kowa Company, Novartis International, Regeneron Pharmaceuticals, and Sirnaomics. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).
Product Specifications
- Format
- paperback
- ASIN
- B0BLQSHQ9P
- Category
- Books > Subjects
- Domain
- Amazon UK
- Release Date
- 26 October 2022
- Listed Since
- 10 November 2022
Similar Products You Might Like
99% match
The 2023-2028 Outlook for Proliferative Diabetic Retinopathy Treatments in China
£495.00
12 Aug 2026
99% match
The 2023-2028 Outlook for Proliferative Diabetic Retinopathy Treatments in Japan
£495.00
13 Aug 2026
99% match
The 2023-2028 Outlook for Diabetic Retinopathy Treatments in China
£495.00
15 Aug 2026
99% match
The 2023-2028 Outlook for Diabetic Retinopathy Treatments in Japan
£495.00
19 Aug 2026
98% match
The 2023-2028 Outlook for Proliferative Diabetic Retinopathy Treatments for US Zip Codes
£490.00
26 Aug 2026
98% match
The 2023-2028 Outlook for Macular Degeneration Treatments in the United States
£520.00
26 Aug 2026
98% match
The 2023-2028 Outlook for Macular Degeneration Treatments in India
£515.00
26 Aug 2026
98% match
The 2023-2028 Outlook for Uveitis Drugs in India
£515.00
28 Aug 2026
97% match
The 2026-2031 World Outlook for Diabetic Macular Edema
£885.00
02 Sep 2026
97% match
Early Events in Diabetic Retinopathy and Intervention Strategies
IntechOpen
£113.24
01 Oct 2026
97% match
The 2023-2028 Outlook for Dry Eye Syndrome Treatments in the United States
£520.00
22 Aug 2026
97% match
Diabetic Retinopathy: Methods and Protocols - Research Guide
Humana
£106.00
02 Oct 2026
97% match
Pathobiology of Diabetic Retinopathy: Diabetes, Diabetic Retinopathy and Medicinal Plants
LAP Lambert Academic Publishing
£66.00
22 Sep 2026
97% match
The 2023-2028 Outlook for Dry Eye Syndrome Treatments in India
£515.00
23 Aug 2026
97% match
The 2023-2028 Outlook for Eye Drops in India
£515.00
26 Aug 2026
97% match
The 2023-2028 Outlook for Macular Degeneration Treatments in Japan
£495.00
11 Aug 2026
97% match
The 2023-2028 Outlook for Myopia and Presbyopia Treatments in the United States
£520.00
11 Aug 2026
97% match
The 2023-2028 Outlook for Vision Care in the United States
£520.00
15 Aug 2026
97% match
The 2023-2028 Outlook for Anti-Vascular Endothelial Growth Factor Therapy (Anti-VEGF) for Non-Infectious Macular Edema in the United States
£520.00
03 Oct 2026
97% match
Therapeutic Targets for Diabetic Retinopathy: A Translational Approach
Elsevier
£33.32
17 Sep 2026
97% match
The 2023-2028 Outlook for Optic Nerve Disorders Treatments in the United States
£520.00
20 Aug 2026
97% match
The 2025-2030 World Outlook for Diabetic Macular Edema
Price unavailable
97% match
Diabetic Retinopathy - IntechOpen Medical Reference
IntechOpen
£130.98
01 Oct 2026
97% match
The 2023-2028 Outlook for Diabetes Care Products in the United States
£520.00
25 Aug 2026